Pfizer COVID-19 vaccine given green light for use in Australia

The TGA has approved the Pfizer COVID-19 vaccine for use in Australia. We take a look at some of the details from the news out of today.

| More on:
covid vaccine shares represented by numbers 2021 with the one displayed as syringe

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This morning, Australia's medical regulator, the Therapeutic Goods Administration (TGA), gave the thumbs up for use of the Pfizer Inc (NYSE: PFE) COVID-19 vaccine, as reported by The ABC.

The approval comes one year after the first recorded case of coronavirus on Australian shores. Pfizer's product is the first COVID-19 vaccine to be approved for use within Australia, beating out other suppliers, including Moderna Inc (NASDAQ: MRNA) and AstraZeneca plc (NYSE: AZN). Health Secretary Professor Brendan Murphy advised that the Australian Government will not be seeking to procure Moderna's vaccine, due to the similarity with Pfizer's.

Prime Minister's comments

Prime Minister, Scott Morrison addressed the public regarding the approval this morning. Mr Morrison noted the premise of today's approval.

This is not an emergency approval, as has been done in some other jurisdictions around the world. This is a formal approval under the ordinary processes of the TGA – and we are one of the first countries, in the handful of countries, to have gone through that comprehensive and thorough process here in Australia, to ensure the approval of that vaccine.

As mentioned in the press briefing held this morning, initial Pfizer vaccines are expected to be rolled out closer to late February than mid-February, due to stresses on global supply.

The impact on supply means that the government's original guide of 4 million people injected by the end of March now looks more likely to be targeted for late April.

Mr Morrison remarked on how this reflects the importance of having domestic manufacturing capability.

..and it was for that reason, around August of last year, that we took the decision that we didn't want to be in a situation where we are completely reliant on the production of vaccines overseas.

The product of that early decision is the working relationship between CSL Limited (ASX: CSL) and AstraZeneca to manufacture 'our own vaccine' here in Australia, pending TGA approval. Overseas supply is expected in early March, with domestic production of the AstraZeneca formulation through CSL to yield around 1 million doses per week by late March.

COVID-19 vaccine details

Reportedly, the Pfizer vaccine will be supplied in Australia for people aged 16 years and older. The inoculation will be provided in two doses, with a minimum of 21 days between each dose.

Professor Murphy also noted that the immunity length is still unknown, "It may be that people will need additional doses of vaccines, possibly annually. These things are completely unknown at the moment."

Additionally reported by The Australian Financial Review, there is currently no data on the Pfizer vaccine's effect on pregnant women. Professor Murphy commented, "We will be getting advice, that is just going to be based on the best guess of what the risks are are at the moment and that is coming very shortly, before the vaccine is administered." 

It is advised that Australia will have access to around 50 million injections of the AstraZeneca vaccine once approved by the TGA.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Coronavirus News

Man with his hand on his face looking at a falling share price chart on a tablet.
Share Market News

ASX 200 stocks dive 2.4% in worst trading day since Ukraine crisis hit

It's not a good start to the week for the market.

Read more »

A woman looks nervous and uncertain holding a hand to her chin while looking at a paper cut out of a plane that she's holding in her other hand. representing the falling Air New Zealand share price today
Travel Shares

Borders just reopened so why is the Flight Centre (ASX:FLT) share price falling today?

Experts believe it may take several years for tourism levels to rebound to pre-pandemic numbers.

Read more »

A worker in hi vis gear holds his hand up saying no.
Coronavirus News

Own BHP (ASX:BHP) shares? Here's how the ASX 200 miner is battling COVID

Mining unions have not generally supported mandatory vaccinations.

Read more »

Female worker sitting desk with head in hand and looking fed up
Coronavirus News

Here's what Rio Tinto (ASX:RIO) boss says is 'causing some challenges' right now

The Omicron variant is spreading in Western Australia.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Coronavirus News

Why are ASX COVID test shares climbing today?

COVID-19 tests are in focus again today.

Read more »

a girl stands in an apple orchard holding two red apples in raised arms with a happy, celebratory look on her face with a large smile and a pretty country background to the picture.
Economy

CBA reveals the Australian economy's leading state amid COVID surge

The states and territories have all been impacted by the pandemic.

Read more »

Rapid Antigen Test taking place.
Share Market News

Why is Ellume hitting headlines today?

Brisbane-based diagnostics developer Ellume is back in the headlines.

Read more »

A woman looks quizzical as she looks at a graph of the share market.
Share Market News

Inghams (ASX:ING) share price sinks as Omicron bites

Inghams shares are down as COVID hurts its operations.

Read more »